

October 16, 2025

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
BSE Scrip Code: 524743

To

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051
NSE Symbol: FISCHER

Dear Sir,

Reg : Press Release: FMV Global Innovation PTE Ltd Secures Full Licensing for Indonesia's End-TB Handheld X-ray Tender

We enclose a press release regarding "**FMV Global Innovation PTE Ltd achieving full licensing status for Indonesia's landmark handheld X-ray government tender**", for dissemination.

Thanking you,
Yours Truly,
For **FISCHER MEDICAL VENTURES LIMITED**



ARAVINDKUMAR V

COMPANY SECRETARY & COMPLIANCE OFFICER



Corporate Office : Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006
Registered Office : No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyanadu Mandal, Visakhapatnam, 530032

FMV Global Innovation PTE Ltd (FMV Global Innovation) Achieves Full Licensing Status for Indonesia’s Landmark Handheld X-ray Government Tender

FMV Global Innovation PTE Ltd, the wholly-owned subsidiary of Fischer Medical Ventures Limited is now one of the fully licensed participants in Indonesia’s End-TB Handheld X-ray Tender. With the licenses secured, the company is poised to support TB elimination by 2030 through strategic local partnerships, pilot projects, AI-enabled diagnostics, and advanced molecular testing solutions.

Jakarta, 16 October 2025 — FMV Global Innovation PTE Ltd (“FMV Global Innovation”) proudly announces that it has achieved full licensing status for Indonesia’s landmark handheld X-ray government tender and is now one of the licensed parties fully eligible to compete in the Indonesia Government’s highly anticipated End-TB Handheld X-ray Tender. FMV Global Innovation has secured all three necessary licenses making it fully compliant and ready to participate in Indonesia’s initiative to eliminate tuberculosis by 2030.

Background and Project Significance

Indonesia’s aggressive TB eradication program, anchored in Presidential Regulation No. 67/2021, positions TB elimination as a critical national goal. The Handheld X-ray Tender forms the core of this strategy, aiming to expand early detection efforts and integrate mobile health technology into primary care and remote communities.

FMV Global Innovation’s journey to this point involved:

- Strategic collaborations with Indian technology providers.
- Partnership with PT Pariko Medical Ventures, to ensure seamless local operations.
- Navigating an intensive licensing process completed in 11 months, securing authority to sell handheld X-ray devices nationwide.



FMV Global Innovation is actively pursuing local manufacturing partnerships, preparing pilot projects to showcase clinical efficacy in Indonesia, and expanding its product portfolio with advanced molecular TB testing kits, AI integration, and better detector solutions—aiming to meet the evolving needs of Indonesia’s health agencies.



Looking Forward

FMV Global Innovation is confident that the upcoming hand-held X-ray tender will be a landmark event within the year. Its strategic positioning, compliance excellence, and ongoing local engagement establish it as a strong contender to support the nation's pathway toward TB elimination.

About FMV Global Innovation

FMV Global Innovation PTE Ltd is dedicated to providing cutting-edge diagnostic solutions, fostering local partnerships, and supporting Indonesia's health system transformation to achieve impactful, sustainable healthcare.

For further information, please contact:

Fischer Medical Ventures Limited

Email: enquiry@fischermv.com

Website: www.fischermv.com

Contact: **9080966548**

Disclaimer:

This investor release is not an offer to sell any securities or a solicitation to buy any securities of Fischer Medical Ventures Limited (the "company") or its subsidiaries (together with the company, the "group"). Certain statements in this document may be forward looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "or" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intention. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Forward looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Investor Release, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. **FISCHERMVL** will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward- looking statements to reflect subsequent events or circumstances.
